IMCD (ENXTAM:IMCD) Unveils Women’s Health Push Following Undervalued Narrative

IMCD (ENXTAM:IMCD) put women’s health in focus at Vitafoods Asia 2026 by unveiling 10 ready-to-market formulations for menopause, hormonal balance, inner wellness, age preservation, and cognitive support that could reshape its specialty ingredients offering.

Recent trading suggests interest in IMCD is picking up, with a 7-day share price return of 3.05% and a 90-day gain of 18.32% helping lift the year-to-date move to 23.55%, even though the 1-year total shareholder return is 8.94% and longer term holders have faced declines over 3 and 5 years.

Scan how IMCD’s women’s health push compares with other specialty ingredient players by reviewing the hand-picked 617 high quality undiscovered gems targeting strong fundamentals and under-the-radar potential.

IMCD shares have performed strongly this year yet still trade at a discount to both analyst targets and intrinsic estimates. Does that gap signal remaining value or a fair warning from the market?

Most Popular Narrative: 17% Undervalued

IMCD last closed at €96.62, while the most followed valuation narrative points to a fair value around €116.57. This frames today’s women’s health push within a broader underpricing story.

IMCD's strategic expansion into high-growth and resilient end-markets (pharma, food & nutrition, personal care) through both organic efforts and targeted M&A increases exposure to industries with strong, recurring demand fundamentals, which can support sustainable revenue and margin expansion as macro uncertainty fades.

See why 13 investors see IMCD as 17% undervalued.

Result: Fair Value of €116.57 (UNDERVALUED)

Still, the IMCD story can change quickly if foreign exchange swings keep pressuring reported earnings or if acquisition risks and integration costs weigh more heavily than expected.

Find out about the key risks to this IMCD narrative.

Another View: IMCD Through The P/E Lens

The SWS DCF model points to IMCD trading well below estimated future cash flow value at €182.80, yet the current P/E of 24.8x tells a different story. That ratio is higher than the fair ratio of 18x, the European Trade Distributors average of 17.5x, and the peer average of 19.5x, which tilts this method toward a richer pricing signal. For anyone weighing these mixed messages, the key question is which lens feels more realistic for the risk and return being taken on.

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With IMCD, the story combines optimism and caution in equal measure. Move fast, scrutinise the data, and weigh the 3 key rewards and 1 important warning sign.

Looking for more ideas beyond IMCD?

Do not stop your research with IMCD when a wider set of opportunities is sitting one click away on the Simply Wall Street Screener.

• Target resilient cash flows and balance sheet strength by reviewing the list of solid balance sheet and fundamentals (205 results).
• Hunt for mispriced quality and see which companies screen as 191 high quality undervalued stocks.
• Prioritise durability and reduced volatility with a hand-picked group of 224 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com